ClinicalTrials.gg
CompletedNCT03452488SARA-INTUpdated Oct 1, 2024Results posted

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

A Phase 2 interventional study of BIO101 and Placebo in Sarcopenia, Gait Disorders in Old Age and Muscle Weakness, sponsored by Biophytis. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Biophytis · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Sarcopenia with a site in United States — 37 open to participants now, 47 under way, 1 of them phase 3. Sarcopenia · United States.

Enrollment
7th of 146
233 · median 40
Started
2017
with 14 others
Phase 2
20 of 187
5 open now
Registered
95th of 187
by date

Among the 187 studies in Sarcopenia with a site in United States, this one is the 7th largest by enrollment of the 146 interventional ones that give a count, is one of 15 that started in 2017, is one of 20 in phase 2, and was the 95th registered.

Sarcopenia

1,329 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

37 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test. The absolute change from baseline in meters/second observed in each treatment group at 6 Month was compared to the placebo group. Due to the Covid pandemic >50% of data at endpoint was missing, which may have affected the ability of the study to deliver the expected results. Additionally, although the planned duration of treatment was 6 months, it was extended up to 9 months for some participants as a result of the pandemic.

Read the detailed description

The aim of this phase 2 double-blind, placebo-controlled, randomized interventional clinical trial (SARA-INT) is to evaluate the safety and efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 9 months oral administration to participants suffering from age-related sarcopenia, including sarcopenic obesity, aged ≥65 years and at risk of mobility disability. There are 3-arms (2 doses versus placebo). This comparative clinical trial evaluated the effects up to 9 month treatment duration, based on the hypothesis that physical function of sarcopenic, older participants with an initial degree of mobility disability (SPPB) may be improved by BIO101.

Included participants were randomized in a 1:1:1 ratio, to one of the 3 arms of treatment in a blinded manner. The randomization was stratified by gender and by center. Based on absence of long-term toxicology data, the investigational drug exposure was initially capped at 6 months.

03

Conditions studied

  • Sarcopenia
  • Gait Disorders in Old Age
  • Muscle Weakness

Keywords

  • Sarcopenia
  • Sarcopenic Obesity
  • 6-minute walking distance
  • 400 meters walking test
  • BIO101
  • Short Physical Performance Battery
  • Appendicular lean mass
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged ≥ 65 years and living in the community, reporting loss of physical function over the last 6-12 months
  4. Short Physical Performance Battery (SPPB) score ≤ 8
  5. ALM/ \< 0.789 in men and 0.512 in women, or ALM \< 19.75kg in men and \<15.02kg in women, as measured by DEXA scan
  6. Ability to take oral medication and be willing to adhere to the study intervention regimen.
  7. Agreement to adhere to Lifestyle Considerations throughout study duration
  8. In the US, women and members of minority groups must be included in accordance with the NIH Policy on Inclusion of Women and Minorities as Participants In Research Involving Human participants.

Exclusion criteria

Exclusion Criteria:

  1. Current use of anabolic drugs (e.g. testosterone); current use of Erythropoietin; current use of agents (except local administration route, like eye drops or dermatologic formulations)
  2. Non-menopaused women (however ongoing replacement hormonal treatment is not an exclusion criterion)
  3. Known allergic reactions to components of the drug.
  4. Treatment with another investigational drug or other intervention within three months
  5. Unable to understand and perform the functional tests, as judged by the Investigator
  6. Inability to perform the 400MW test within 15 minutes
  7. Clinical conditions:

    1. Current diagnosis of major psychiatric disorders.
    2. Alcohol abuse or dependence
    3. Severe arthritis
    4. Cancer requiring active treatment (cancer treated with chemotherapy, or radiotherapy and currently on remission is not an exclusion criterion)
    5. Lung disease requiring regular use of supplemental oxygen
    6. Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents
    7. Severe cardiovascular disease (including [NYHA] class III or IV congestive heart failure, valvular disease, history of cardiac arrest, presence of an implantable defibrillator, or uncontrolled angina)
    8. Parkinson's disease or other progressive neurological disorder
    9. Renal disease requiring dialysis, or known renal insufficiency (moderate or severe reduction in ≤30 ml/min/1.73 m2)
    10. Chest pain, severe shortness of breath, or occurrence of other safety concerns during the baseline functional tests 400-meter walk test or 6MWT
    11. History or active signs or symptoms of gallbladder/biliary disease (e.g. previous episodes of cholestasis/biliary tract obstruction, cholelithiasis, cholecystitis, etc.). Of note, history of cholecystectomy and no active biliary signs or symptoms, is not an exclusion criterion.
  8. Current physical/rehabilitation therapy (except for passive physical therapy. However, this should not be initiated the week before an evaluation visit and once started, it should be maintained over the study duration).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
233 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.

    Drug: Placebo

  • Experimental
    175mg BIO101

    BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.

    Drug: BIO101

  • Experimental
    350mg BIO101

    BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.

    Drug: BIO101

Interventions

  • DrugBIO101

    Oral capsules

    Also known as: 20 hydroxyecdysone (20E)

  • DrugPlacebo

    Oral capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test

    Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

Secondary outcomes

  1. Change From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score

    The Physical Function Domain (PF-10) of the SF-36 assesses an individual's perceived physical functioning and limitations in various activities. It consists of ten items that ask about a person's ability to perform different physical activities and tasks. Scores on the PF-10 range from 0 to 100 where 100 indicates no physical limitations. Missing data imputed using adjusted Bayesian MI methods. Data up to 9 month was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  2. Change From Baseline to 6 Months in Handgrip Strength Test

    Handgrip strength was a commonly used measure of upper body skeletal muscle function and had been widely used as a general indicator of frailty with predictive validity for both mortality and functional limitations. Participants were instructed to stand upright and with the dynamometer beside them but not against their body. Strength was measured three times for both hands. The highest value of all 3 attempts was kept for further analysis. Grip strength was measured in the dominant hand using a hydraulic grip strength dynamometer. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  3. Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements

    DEXA scans provided accurate measurements of body composition, recording fat and lean mass distribution throughout the entire body. Foundation of National Health Institute (FNIH) project report recommended ALM alone was used to measure gender-specific low muscle mass. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  4. Rate of Response for Completing 400 MW Test After 6 Months

    A responder was defined as an improvement (increase) of 0.1 m/s or more in 400MW gait speed test compared to baseline. A non-responder was defined as a participant that was not a responder. Participants with a missing value at the visit and/or missing baseline value were considered as non-responders. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  5. Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension

    Isometric knee extension torque was measured with a knee extension dynamometer chair. The participants were positioned in an upright position, with straps to affix the hips to the chair and the ankle to a force or torque transducer at the knee angle of 90°. Lever arm length was recorded as the distance between the knee axis of rotation and the middle of the pad. Knee extension was measured using the maximum peak torque measurement Newton meter (Nm) for 60°/s, 90°/s and 180°/s for the tested leg (either right or left). The Knee extension torque was obtained either directly or by multiplying recorded peak force with the lever arm length. The assay with the highest torque output was taken for analyses. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  6. Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment

    The SPPB was a series of tests designed to examine physical movements. The chair stands tests involved standing from a chair a number of times to test leg strength. Each performance measures were assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. The time to complete the task was recorded. The time required to perform five chair stands was scored as follows: ≥ 16.70 sec = 1; 13.70 to 16.69 sec = 2; 11.20 to 13.69 sec = 3; ≤ 11.19 = 4. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the chair stands test. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  7. Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)

    The 6MWT was a test for functional exercise capacity and involved measuring the distance a participant could cover within the allotted time of 6 minutes. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  8. Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants

    The PAT-D was a disability questionnaire which asked respondents how much difficulty they had with a range of activities with functioning. PAT-D scores range from 1 (worst) to 5 (best). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  9. Change From Baseline to 6 Months in SPPB Total Score

    The SPPB was a series of tests designed to examine physical movements. Results of the SPPB included total gait speed score, total balance test score, and total chair stand score. The first tests examined balance (without the assistance of a cane or walker) with the feet in three different orientations, the second test examined gait speed, and the third tests involved standing from a Chair a number of times to test leg strength. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the walking speed, chair stands and balance tests. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  10. Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire

    The SarQoL was a sarcopenia-specific, self-administered, quality of life questionnaire designed for community-dwelling elderly study participants aged 65 years and older. The questionnaire contained 22 questions, which took approximately 10 minutes to complete. The questionnaire covered 7 domains: physical and mental health; locomotion; body composition; functionality; activities of daily living; leisure activities; and fears. Most questions are answered on a 4 point Likert scale. The total scoring of the SarQoL questionnaire ranges from 0 (worst imaginable health) to 100 (best imaginable health). A higher score reflected a higher quality of life. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

  11. Change From Baseline to 6 Months in Stair Climb Power Test (SCPT)

    The SCPT measured the ability to ascend and descend stairs and tests lower body strength and balance and measures time (in seconds) taken to ascend and descend a flight of stairs (10 steps with a 20 cm step height; a handrail was recommended). Step heights should have been suitable (between 16 and 20 cm). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

    Time frame: Baseline and 6 Months

07

Results

Posted Oct 1, 2024
Limitations and caveats
Due to the coronavirus disease 2019 (COVID-19) outbreak, the implementation of the clinical protocol was affected, including but not limited to the scheduled site visit for safety and/or efficacy, site visits for monitoring, investigational product delivery, collection of adverse events (AEs) and concomitant medications. This led to \>50% loss of efficacy data for the primary endpoint and other performance assessments.

Participant flow

Participants were enrolled from 19 centers in the United States and 3 centers in Belgium.

Participant flow — Overall Study
MilestonePlacebo175mg BIO101350mg BIO101
Started817676
Completed706469
Not completed11127
Withdrew: Adverse event461
Withdrew: Death001
Withdrew: Lost to follow-up120
Withdrew: Pi decision100
Withdrew: Withdrew consent422
Withdrew: Withdraw due to the covid-19 outbreak101
Withdrew: Other022

Outcome measures

PrimaryChange From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test

Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Meter/Second (m/s)
Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test
Meter/Second (m/s)Placebo175mg BIO101350mg BIO101
Gait Speed based on Mixed Effect Model0.0093 (-0.0369 to 0.0556)0.0457 (-0.0014 to 0.0927)0.0478 (0.0050 to 0.0907)
Gait Speed Based on Adjusted Bayesian Imputation-0.2886 (-0.3641 to -0.2132)-0.2543 (-0.3347 to -0.1738)-0.2014 (-0.2790 to -0.1238)
MI + Adjusted Bayesian Imputation-0.0188 (-0.0743 to 0.0366)-0.0066 (-0.0547 to 0.0415)0.0500 (-0.0013 to 0.1013)
Statistical analysis
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.2437
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.2000
  • Placebo vs 175mg BIO101 · Adjusted Bayesian Imputation · p = 0.3240
  • Placebo vs 350mg BIO101 · Adjusted Bayesian Imputation · p = 0.5123
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.6920
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.0850
SecondaryChange From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score

The Physical Function Domain (PF-10) of the SF-36 assesses an individual's perceived physical functioning and limitations in various activities. It consists of ten items that ask about a person's ability to perform different physical activities and tasks. Scores on the PF-10 range from 0 to 100 where 100 indicates no physical limitations. Missing data imputed using adjusted Bayesian MI methods. Data up to 9 month was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score
score on a scalePlacebo175mg BIO101350mg BIO101
Analysis based on Mixed Effect Model for MMRM7.3 (2.4 to 12.3)7.1 (1.9 to 12.3)7.1 (2.2 to 12.1)
Based on Adjusted Bayesian Imputation1.4 (-4.8 to 7.6)4.0 (-2.1 to 10.1)4.1 (-1.7 to 9.8)
Statistical analysis
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.9408
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.9485
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.9848
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.5017
SecondaryChange From Baseline to 6 Months in Handgrip Strength Test

Handgrip strength was a commonly used measure of upper body skeletal muscle function and had been widely used as a general indicator of frailty with predictive validity for both mortality and functional limitations. Participants were instructed to stand upright and with the dynamometer beside them but not against their body. Strength was measured three times for both hands. The highest value of all 3 attempts was kept for further analysis. Grip strength was measured in the dominant hand using a hydraulic grip strength dynamometer. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · kilograms (Kg)
Change From Baseline to 6 Months in Handgrip Strength Test
kilograms (Kg)Placebo175mg BIO101350mg BIO101
Handgrip strength Test at Month 6 (dominant hand)-0.709 (-2.902 to 1.484)-1.601 (-3.935 to 0.733)0.590 (-1.533 to 2.712)
Handgrip strength test at month 6 (Left hand)-0.860 (-2.852 to 1.131)-1.597 (-3.766 to 0.573)0.319 (-1.626 to 2.264)
Handgrip strength test at month 6 (Right hand)-0.842 (-3.098 to 1.414)-1.664 (-3.993 to 0.665)0.865 (-1.262 to 2.992)
Based on Multiple Imputation (dominant hand)0.145 (-2.270 to 2.561)0.297 (-2.194 to 2.788)0.663 (-1.822 to 3.148)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.5200
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.3577
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.9237
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.7629
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.5695
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.3523
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.5652
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.2472
SecondaryChange From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements

DEXA scans provided accurate measurements of body composition, recording fat and lean mass distribution throughout the entire body. Foundation of National Health Institute (FNIH) project report recommended ALM alone was used to measure gender-specific low muscle mass. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Kg
Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements
KgPlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements-0.276 (-0.911 to 0.359)-0.283 (-0.944 to 0.378)0.068 (-0.496 to 0.632)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.9859 (Statistical Analysis of Change from Baseline in ALM)
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.4040
SecondaryRate of Response for Completing 400 MW Test After 6 Months

A responder was defined as an improvement (increase) of 0.1 m/s or more in 400MW gait speed test compared to baseline. A non-responder was defined as a participant that was not a responder. Participants with a missing value at the visit and/or missing baseline value were considered as non-responders. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Count of participants · Participants
Rate of Response for Completing 400 MW Test After 6 Months
ParticipantsPlacebo175mg BIO101350mg BIO101
Responder4911
Non-responder776665
Statistical analysis
  • Placebo vs 175mg BIO101 · Regression, Logistic · p = 0.1219
  • Placebo vs 350mg BIO101 · Regression, Logistic · p = 0.0520
SecondaryChange From Baseline to 6 Months in Muscle Strength Based on Knee Extension

Isometric knee extension torque was measured with a knee extension dynamometer chair. The participants were positioned in an upright position, with straps to affix the hips to the chair and the ankle to a force or torque transducer at the knee angle of 90°. Lever arm length was recorded as the distance between the knee axis of rotation and the middle of the pad. Knee extension was measured using the maximum peak torque measurement Newton meter (Nm) for 60°/s, 90°/s and 180°/s for the tested leg (either right or left). The Knee extension torque was obtained either directly or by multiplying recorded peak force with the lever arm length. The assay with the highest torque output was taken for analyses. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Newton meter (Nm)
Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension
Newton meter (Nm)Placebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension0.484 (-18.088 to 19.056)-1.092 (-21.833 to 19.649)-4.515 (-17.889 to 8.858)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.8917
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.6317 · Mean difference (final values): -4.999 · 95% CI -26.777 to 16.778
SecondaryChange From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment

The SPPB was a series of tests designed to examine physical movements. The chair stands tests involved standing from a chair a number of times to test leg strength. Each performance measures were assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. The time to complete the task was recorded. The time required to perform five chair stands was scored as follows: ≥ 16.70 sec = 1; 13.70 to 16.69 sec = 2; 11.20 to 13.69 sec = 3; ≤ 11.19 = 4. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the chair stands test. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Seconds
Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment
SecondsPlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment-3.857 (-6.024 to -1.690)-2.572 (-4.721 to -0.422)-1.206 (-3.135 to 0.724)
Statistical analysis
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.3762
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.0543
SecondaryChange From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)

The 6MWT was a test for functional exercise capacity and involved measuring the distance a participant could cover within the allotted time of 6 minutes. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Meters
Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)
MetersPlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)-9.879 (-37.089 to 17.330)-7.166 (-36.559 to 22.228)15.728 (-10.981 to 42.436)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.8824
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.1578
SecondaryChange From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants

The PAT-D was a disability questionnaire which asked respondents how much difficulty they had with a range of activities with functioning. PAT-D scores range from 1 (worst) to 5 (best). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants
score on a scalePlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants-0.27 (-0.42 to -0.13)-0.08 (-0.24 to 0.08)-0.17 (-0.31 to -0.03)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.0511
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.2771
SecondaryChange From Baseline to 6 Months in SPPB Total Score

The SPPB was a series of tests designed to examine physical movements. Results of the SPPB included total gait speed score, total balance test score, and total chair stand score. The first tests examined balance (without the assistance of a cane or walker) with the feet in three different orientations, the second test examined gait speed, and the third tests involved standing from a Chair a number of times to test leg strength. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the walking speed, chair stands and balance tests. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline to 6 Months in SPPB Total Score
score on a scalePlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in SPPB Total Score1.1 (0.5 to 1.6)1.00 (0.4 to 1.5)0.9 (0.3 to 1.5)
Statistical analysis
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.8084
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.7266
SecondaryChange From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire

The SarQoL was a sarcopenia-specific, self-administered, quality of life questionnaire designed for community-dwelling elderly study participants aged 65 years and older. The questionnaire contained 22 questions, which took approximately 10 minutes to complete. The questionnaire covered 7 domains: physical and mental health; locomotion; body composition; functionality; activities of daily living; leisure activities; and fears. Most questions are answered on a 4 point Likert scale. The total scoring of the SarQoL questionnaire ranges from 0 (worst imaginable health) to 100 (best imaginable health). A higher score reflected a higher quality of life. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · score on a scale
Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire
score on a scalePlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire8.05 (4.95 to 11.14)5.60 (2.43 to 8.78)5.83 (2.79 to 8.87)
Statistical analysis
  • Placebo vs 175mg BIO101 · Mixed Models Analysis · p = 0.2312
  • Placebo vs 350mg BIO101 · Mixed Models Analysis · p = 0.2701
SecondaryChange From Baseline to 6 Months in Stair Climb Power Test (SCPT)

The SCPT measured the ability to ascend and descend stairs and tests lower body strength and balance and measures time (in seconds) taken to ascend and descend a flight of stairs (10 steps with a 20 cm step height; a handrail was recommended). Step heights should have been suitable (between 16 and 20 cm). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Seconds
Change From Baseline to 6 Months in Stair Climb Power Test (SCPT)
SecondsPlacebo175mg BIO101350mg BIO101
Change From Baseline to 6 Months in Stair Climb Power Test (SCPT)39.9 (-46.4 to 126.3)32.4 (-65.4 to 130.3)88.5 (5.1 to 171.8)
Statistical analysis
  • Placebo vs 175mg BIO101 · ANCOVA · p = 0.8934
  • Placebo vs 350mg BIO101 · ANCOVA · p = 0.3526

Adverse events

Collected over Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/81 (1.2%)10/81 (12.3%)48/81 (59.3%)
175mg BIO1010/75 (0%)10/75 (13.3%)45/75 (60%)
350mg BIO1011/74 (1.4%)4/74 (5.4%)38/74 (51.4%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPlacebo175mg BIO101350mg BIO101
Partial bowel obstructionGastrointestinal disorders0/810/751/74
Orthostatic hypotensionVascular disorders0/810/751/74
Coronavirus infectionInfections and infestations0/810/751/74
Chest painMusculoskeletal and connective tissue disorders0/810/751/74
Ischemic strokeCardiac disorders0/811/750/74
Recurrent cardiac decompensationCardiac disorders0/811/750/74
Unstable anginaCardiac disorders0/811/750/74
ToothacheGastrointestinal disorders0/811/750/74
Cellulitis of legInfections and infestations0/811/750/74
Fracture of intertrochanteric section of femur, closedInjury, poisoning and procedural complications0/811/750/74
Most frequent other events
Showing 10 of 216
Most frequent other events
EventPlacebo175mg BIO101350mg BIO101
FallInjury, poisoning and procedural complications4/812/753/74
DiarrheaGastrointestinal disorders0/813/751/74
Urinary tract infectionRenal and urinary disorders0/813/750/74
ConstipationGastrointestinal disorders3/810/751/74
NauseaGastrointestinal disorders0/812/752/74
ArthritisMusculoskeletal and connective tissue disorders0/810/752/74
FallMusculoskeletal and connective tissue disorders1/810/752/74
BronchitisRespiratory, thoracic and mediastinal disorders0/810/752/74
FluInfections and infestations0/812/750/74
Myalgia of lower extremitiesMusculoskeletal and connective tissue disorders0/812/750/74

Baseline characteristics

One participant randomized but not treated with 175 mg BIO101.

Age, Continuous
Age, Continuous(Years)Placebo175mg BIO101350mg BIO101Total
Mean75.5 ± 7.1276.2 ± 7.1076.3 ± 6.3876.0 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)Placebo175mg BIO101350mg BIO101Total
Female443738119
Male373838113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo175mg BIO101350mg BIO101Total
American Indian or Alaska Native0000
Asian13131440
Native Hawaiian or Other Pacific Islander0000
Black or African American37111
White655561181
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Placebo175mg BIO101350mg BIO101Total
Belgium76720
United States746969212
08

Study locations

22 sites
  • Advanced Clinical Research
    Banning, California 92221, United States
  • SC Clinical Research, Inc
    Garden Grove, California 92844, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Institut On Aging
    Gainesville, Florida 32611, United States
  • Jax-Ascent University of Florida
    Jacksonville, Florida 32209, United States
  • PANAX Clinical Research
    Miami Lakes, Florida 33014, United States
  • Clinical Research of Central Florida
    Plant City, Florida 33563, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Jean Mayer USDA Human Nutrition research Center on Aging Tufts University
    Boston, Massachusetts 02111, United States
  • New Mexico Clinical Research & Osteoporosis Center
    Albuquerque, New Mexico 87106, United States
  • Columbia University
    New York, New York 10032, United States
  • PMJ Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Bowman Gray Center for Medical Education-of- Wake Forest School of Medicine
    Winston-Salem, North Carolina 27101, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Medical Center
    Houston, Texas 77030, United States
  • Science Advancing Medicine Clinical Research Center
    San Antonio, Texas 78229, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78245, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Vrije Universiteit Brussel
    Bruxelles, 1090, Belgium
  • Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Centrum voor metabole botziekten
    Leuven, 3000, Belgium
  • Université de Liège
    Liège, 4020, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2020, 38 months.

Results were first posted in Oct 2024, 4 years 5 months after primary completion.

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2018
First posted
Mar 2, 2018
StartActual
Feb 7, 2017
Primary completionActual
Apr 26, 2020
CompletionActual
Apr 26, 2020
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03452488
Lead sponsor
Biophytis
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Feb 7, 2017
Primary completion
Apr 26, 2020
Completion
Apr 26, 2020
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Rob Van Maanen
study director · Biophytis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ecdystene

Start the discussion